Explore

Trendline Trendline
AstraZeneca Engages in Talks with Bristol Myers Squibb for Potential $400 Billion Merger

AstraZeneca Engages in Talks with Bristol Myers Squibb for Potential $400 Billion Merger

AstraZeneca Engages in Talks with Bristol Myers Squibb for Potential $400 Billion Merger
Reuters Reuters
AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports

AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca's shares fell as investors balked on Monday at reports of merger talks with Bristol Myers Squibb about forming what would become one of the world's biggest drugmakers with a combined value of nearly $400 billion.
Trendline Trendline
AstraZeneca's Potential $400bn Merger with Bristol Myers Squibb Raises Concerns

AstraZeneca's Potential $400bn Merger with Bristol Myers Squibb Raises Concerns

AstraZeneca's Potential $400bn Merger with Bristol Myers Squibb Raises Concerns
Reuters Reuters
AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca investors punished the pharmaceutical firm on Monday over reports of merger talks with U.S. rival Bristol Myers Squibb that could make one of the world's biggest drugmakers with a combined value of nearly $400 billion.
Trendline Trendline
AstraZeneca Considers Major Merger with Bristol Myers Squibb Amid CEO's Previous Denial

AstraZeneca Considers Major Merger with Bristol Myers Squibb Amid CEO's Previous Denial

AstraZeneca Considers Major Merger with Bristol Myers Squibb Amid CEO's Previous Denial
Trendline Trendline
AstraZeneca Explores Potential Merger with Bristol Myers Squibb Amid Patent Concerns

AstraZeneca Explores Potential Merger with Bristol Myers Squibb Amid Patent Concerns

AstraZeneca Explores Potential Merger with Bristol Myers Squibb Amid Patent Concerns
Trendline Trendline
AstraZeneca Shares Drop Amid Merger Talks with Bristol Myers Squibb

AstraZeneca Shares Drop Amid Merger Talks with Bristol Myers Squibb

AstraZeneca Shares Drop Amid Merger Talks with Bristol Myers Squibb
Reuters Reuters
AstraZeneca investors baulk at $400 billion Bristol Myers talks

AstraZeneca investors baulk at $400 billion Bristol Myers talks

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca's shares fell sharply on Monday as investors baulked at reports of merger talks with Bristol Myers Squibb about forming what would become one of the world's biggest drugmakers with a combined value of nearly $400 billion.
Trendline Trendline
AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger
Trendline Trendline
AstraZeneca Explores Potential Merger with Bristol Myers Squibb

AstraZeneca Explores Potential Merger with Bristol Myers Squibb

AstraZeneca Explores Potential Merger with Bristol Myers Squibb
Trendline Trendline
AstraZeneca Pursues $400 Billion Merger with Bristol Myers Squibb Amid Antitrust Concerns

AstraZeneca Pursues $400 Billion Merger with Bristol Myers Squibb Amid Antitrust Concerns

AstraZeneca Pursues $400 Billion Merger with Bristol Myers Squibb Amid Antitrust Concerns
Trendline Trendline
AstraZeneca Shares Drop Amid $400 Billion Merger Talks with Bristol Myers Squibb

AstraZeneca Shares Drop Amid $400 Billion Merger Talks with Bristol Myers Squibb

AstraZeneca Shares Drop Amid $400 Billion Merger Talks with Bristol Myers Squibb